|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:ATCCode
|
gptkb:J05AX15
|
|
gptkbp:bioavailability
|
~80%
|
|
gptkbp:blackBoxWarning
|
risk of hepatitis B reactivation
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:category
|
direct-acting antiviral
|
|
gptkbp:drugClass
|
antiviral drug
inhibits hepatitis C virus replication
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:eliminationHalfLife
|
0.4 hours (parent), 27 hours (metabolite)
|
|
gptkbp:FDAApproved
|
true
|
|
gptkbp:halfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007 metabolite)
|
|
gptkbp:hasBioequivalence
|
not established with food
|
|
gptkbp:hasDrugBankURL
|
https://go.drugbank.com/drugs/DB09278
|
|
gptkbp:hasEMAApproval
|
true
|
|
gptkbp:hasInChIKey
|
YYOQXSRSLFDJOM-QZIXMDIESA-N
|
|
gptkbp:hasMolecularFormula
|
C22H29FN3O9P
|
|
gptkbp:hasPatentHolder
|
gptkb:Gilead_Sciences
|
|
gptkbp:hasSMILES
|
CC(C)COC(=O)[C@H](NC(=O)[C@@H]1O[C@@](CN2C=NC3=C2N=CN=C3N)([C@H](O1)CO)CO)P(=O)(O)O
|
|
gptkbp:hasUNII
|
Q1Q1X67J8U
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB09278
|
|
gptkbp:indication
|
treatment of hepatitis C
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isUsedInCombinationWith
|
ribavirin
ledipasvir
velpatasvir
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:marketedAs
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
NS5B RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
529.45
|
|
gptkbp:name
|
gptkb:Sofosbuvir
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
|
|
gptkbp:proteinBinding
|
61-65%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
gptkb:D10366
45375808
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
|
gptkbp:synonym
|
gptkb:Sovaldi
gptkb:GS-7977
gptkb:PSI-7977
|
|
gptkbp:target
|
NS5B polymerase
|
|
gptkbp:bfsParent
|
gptkb:alirocumab
|
|
gptkbp:bfsLayer
|
7
|